NASDAQ
BioNexus Gene Lab Corp. (BGLC) has a free cash flow growth of -115.42% as of Friday, May 29, 2026. This represents a 61.68% increase compared to its 12-month average of -301.21%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.